Why the Medical Developments International (ASX:MVP) share price is rocketing 32% higher

It has been a good day for this healthcare share…

| More on:
Rocket powering up and symbolising a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • Medical Developments International has been given a major boost in the US.
  • This morning the company revealed that the US FDA has lifted its clinical hold on the Penthrox product.
  • This means the company can now push ahead with its plans for a Phase III US clinical trial.

The Medical Developments International Ltd (ASX: MVP) share price has returned from its trading halt with a bang.

In morning trade, the medical device company's shares are up a massive 32% to $4.50.

Why is the Medical Developments International share price shooting higher?

The Medical Developments International share price returned to trade this morning following the release of an announcement relating to its US aspirations for the Penthrox (aka the green whistle) product.

According to the release, the US Food and Drug Administration (FDA) has unconditionally lifted the agency's clinical hold on Penthrox.

As a result, this means that Medical Developments International can immediately begin preparing for its Phase III US clinical trial.

The release explains that the trial will be conducted on a targeted trauma and associated pain patient group and is expected to run for two years. The company intends to commence recruitment for the trial in late 2022. This means a long-awaited US launch is now a possibility in the coming years.

Management commentary

Medical Developments International's CEO, Brent MacGregor, was delighted with the news.

He said: "We are thrilled with this news which allows us to move forward quickly with preparations for our clinical trial. After years of hard work, our team is buoyed by the prospect of bringing the many benefits of Penthrox to the US market. This will strongly complement our growing Penthrox success in Europe, and fully supports our further investment in the product."

This sentiment was echoed by the company's Chair, Gordon Naylor.

He commented: "This news is important as it brings Penthrox a step closer to licensure in the US market and because the FDA is seen as a global regulatory leader. Our renewed focus on the core business continues to yield results."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »